BioTech IP Review

Patent Title: The Use of CD40 Inhibitors for Inhibiting an Immune Response and Enabling Immunogen Administration and Re‑Administration
Publication Number: WO/2025/184603
Application Number: PCT/US2025/017984
Filing Date: February 28, 2025
Publication Date: September 4, 2025
Applicant: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA)

---

What This Patent Covers

This patent application describes methods and compositions involving CD40 inhibitors to modulate the immune system—specifically:

• CD40 pathway inhibition: CD40 is a key receptor on antigen‑presenting cells like dendritic cells and B cells that activates immune responses. CD40 inhibitors can suppress unwanted immune activation, which has broad therapeutic relevance in autoimmunity, transplant rejection, inflammatory disorders, and immune‑related adverse events.
• Immunogen administration and re‑administration: The invention includes methods for administering or re‑administering immunogenic agents (e.g., vaccines or biologic therapies) in the presence of CD40 inhibition. This can reduce immune responses against therapeutic proteins, enabling repeated dosing of biologics that might otherwise provoke anti‑drug antibodies.
• Compositions and regimes: Likely claims cover the CD40‑blocking agents (e.g., antibodies or small molecules), dosing protocols, and their use with immunogens and biologic drugs to improve safety and efficacy.

In essence, this technology is about controlling the immune system to improve how biologics, vaccines, or gene therapies are tolerated and repeatedly administered.

---

Why This Patent Is Important

1) Broad therapeutic potential
Technologies that modulate CD40 signaling have applications in autoimmune diseases, transplant medicine, chronic inflammation, and immune‑related side effects of biologics. A platform enabling safer re‑administration of advanced therapeutics could be extremely valuable across many indications.

2) Enabler for next‑generation biologics and vaccines
By suppressing adverse immune responses against therapeutic proteins or vectors, CD40 inhibitors can help extend the effectiveness and repeat usability of biologics, gene therapies, or vaccines, which is a major commercial driver in biotech.

3) Strategic IP position
This patent strengthens Regeneron’s intellectual property portfolio in immunology and biologic drug administration, positioning the company to protect or license innovative combinations and treatment regimens.